Kristin Thorp, MD
Hematology & Oncology · Oklahoma City, OKNPI 1700927142
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,382 of the $3,010 with a category attached, or 79.1%. It is spread thinly across 22 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $898, more than ten times the $15 reported in 2019.
Across 143 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$569
- Pfizer$546
- AbbVie$369
- Astellas Pharma US Inc$291
- Merck$242
- Lilly USA, LLC$149
- plus $845 from 16 others
What the payments were for
- Food & beverage$2,38279%
- Education$42914%
- Other$1997%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 23 | $569 |
| Pfizer | 32 | $546 |
| AbbVie | 22 | $369 |
| Astellas Pharma US Inc | 12 | $291 |
| Merck | 11 | $242 |
| Lilly USA, LLC | 3 | $149 |
| AstraZeneca | 1 | $124 |
| Bristol Myers Squibb | 6 | $111 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $98 |
| Daiichi Sankyo Inc. | 4 | $91 |
| GSK | 4 | $65 |
| Array Biopharma Inc | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Gilead(2 entities) | 3 | $45 |
| Genentech USA, Inc. | 2 | $35 |
| ADC Therapeutics America, Inc. | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $32 |
| Johnson & Johnson | 2 | $27 |
| Sobi, Inc | 1 | $19 |
| CTI Biopharma Corp. | 1 | $16 |
| Geron Corporation | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,010 in reported general payments places this provider in the 60th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 42 | $688,127 |
| RevlimidLenalidomide | 24 | $405,040 |
| CalquenceAcalabrutinib Maleate | 32 | $381,845 |
| TasignaNilotinib Hcl | 21 | $328,025 |
| IbrancePalbociclib | 20 | $316,270 |
| KisqaliRibociclib Succinate | 20 | $290,495 |
| PomalystPomalidomide | 11 | $235,010 |
| Kisqali Femara Co-PackRibociclib Succinate/Letrozole | 14 | $211,027 |
| TagrissoOsimertinib Mesylate | 12 | $201,859 |
| SprycelDasatinib | 12 | $175,224 |
| VenclextaVenetoclax | 18 | $47,677 |
| EliquisApixaban | 36 | $43,737 |
| Abiraterone Acetate | 11 | $24,750 |
| SorafenibSorafenib Tosylate | 11 | $23,233 |
| Anastrozole | 297 | $10,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $98 | $688,12742 claims |
| NovartisTasigna, Kisqali | $569 | $618,52041 claims |
| AstraZenecaCalquence, Tagrisso | $124 | $583,70444 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $57 | $410,23423 claims |
| Bristol Myers SquibbRevlimid | $111 | $405,04024 claims |
| PfizerIbrance, Eliquis | $546 | $360,00756 claims |
| AbbVieVenclexta | $369 | $47,67718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 118 hematology & oncology providers in Oklahoma.
Other hematology & oncology in Oklahoma City
- Romeo MandanasOklahoma City$160K
- Mohammad RazaqOklahoma City$56K
- Sami IbrahimiOklahoma City$41K
- Jennifer Holter-ChakrabartyOklahoma City$39K
- Hassan HatoumOklahoma City$23K
- Abdul Rafeh NaqashOklahoma City$23K
- Taha Al-JuhaishiOklahoma City$23K
- Adanma Anji Ayanambakkam AttanathiOklahoma City$16K
- Robert ReynoldsOklahoma City$15K
- Sadia ChohanOklahoma City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.